Qiao Liu

发表

Cost-effectiveness analysis of pembrolizumab plus chemotherapy as first-line therapy for extensive-stage small-cell lung cancer

Chongqing Tan, Qiao Liu, X. Luo, 2021, PloS one.

Cost-effectiveness analysis of pembrolizumab plus chemotherapy for previously untreated metastatic non-small cell lung cancer in the USA

Chongqing Tan, Qiao Liu, Liubao Peng, 2019, BMJ Open.

Cost-Effectiveness of Bevacizumab Biosimilar LY01008 Combined With Chemotherapy as First-Line Treatment for Chinese Patients With Advanced or Recurrent Nonsquamous Non-Small Cell Lung Cancer

Zhen Zhou, Chongqing Tan, Qiao Liu, 2022, Frontiers in Pharmacology.

Cost-Effectiveness Analysis of Adding Daratumumab to a Regimen of Bortezomib, Melphalan, and Prednisone in Newly Diagnosed Multiple Myeloma

Chongqing Tan, Qiao Liu, X. Luo, 2021, Advances in Therapy.

First-Line Chemo-Immunotherapy for Extensive-Stage Small-Cell Lung Cancer: A United States-Based Cost-Effectiveness Analysis

Chongqing Tan, Qiao Liu, X. Luo, 2021, Frontiers in Oncology.

Cost-Effectiveness of Ipilimumab Plus Anti-PD-1 Therapy Versus Ipilimumab Alone in Patients With Metastatic Melanoma Resistant to Anti-PD-(L)1 Monotherapy

Chongqing Tan, Qiao Liu, X. Luo, 2021, Frontiers in Oncology.

Cost-Effectiveness of Nivolumab Plus Ipilimumab Combined with Two Cycles of Chemotherapy as First-Line Treatment in Advanced Non-Small Cell Lung Cancer

Chongqing Tan, Qiao Liu, X. Luo, 2021, Advances in Therapy.

Efficacy and safety of intravenous acetaminophen (2 g/day) for reducing opioid consumption in Chinese adults after elective orthopedic surgery: A multicenter randomized controlled trial

Tinghua Wang, Liulin Xiong, Qiao Liu, 2022, Frontiers in Pharmacology.

The Cost-Effectiveness of Tislelizumab Plus Chemotherapy for Locally Advanced or Metastatic Nonsquamous Non-Small Cell Lung Cancer

Zhen Zhou, Qiao Liu, X. Luo, 2022, Frontiers in Pharmacology.

Cost-effectiveness analysis of tislelizumab, nivolumab and docetaxel as second- and third-line for advanced or metastatic non-small cell lung cancer in China

Zhen Zhou, Chongqing Tan, Qiao Liu, 2022, Frontiers in Pharmacology.

Cost-Effectiveness of Pembrolizumab Plus Chemotherapy Versus Pembrolizumab Monotherapy in Metastatic Non-Squamous and Squamous NSCLC Patients With PD-L1 Expression ≥ 50%

Chongqing Tan, Qiao Liu, X. Luo, 2022, Frontiers in Pharmacology.

Cost-effectiveness of ensartinib, crizotinib, ceritinib, alectinib, brigatinib and lorlatinib in patients with anaplastic lymphoma kinase-positive non-small cell lung cancer in China

Zhen Zhou, Qiao Liu, Liubao Peng, 2022, Frontiers in Public Health.

Lung cancer screening with low-dose computed tomography: National expenditures and cost-effectiveness

Qiao Liu, Xiaohui Zeng, Xia Luo, 2022, Frontiers in Public Health.

Economic evaluation of FLOT and ECF/ECX perioperative chemotherapy in patients with resectable gastric or gastro-oesophageal junction adenocarcinoma

Qiao Liu, Xiaohui Zeng, Chunjiang Wang, 2022, BMJ Open.

Cost-Effectiveness Analysis of Nivolumab Plus Ipilimumab for Advanced Non-Small-Cell Lung Cancer

Qijian Deng, Chongqing Tan, Qiao Liu, 2021, Frontiers in Pharmacology.

Nivolumab Versus Docetaxel for Previously Treated Advanced Non-Small Cell Lung Cancer in China: A Cost-Effectiveness Analysis

Chongqing Tan, Qiao Liu, Liubao Peng, 2019, Clinical Drug Investigation.

Cost-effectiveness analysis of adding ramucirumab to the first-line erlotinib treatment for untreated EGFR-mutated metastatic non-small cell lung cancer in China

Chongqing Tan, Qiao Liu, Liubao Peng, 2020, BMJ Open.

Alpha emitter radium-223 in patients with metastatic castration-resistant prostate cancer: A cost-utility analysis

Chongqing Tan, Qiao Liu, X. Wan, 2022, Frontiers in Pharmacology.

Sintilimab Plus Bevacizumab Biosimilar Versus Sorafenib as First-Line Treatment for Unresectable Hepatocellular Carcinoma: A Cost-Effectiveness Analysis

Chongqing Tan, Qiao Liu, Liubao Peng, 2022, Frontiers in Pharmacology.

Cost-effectiveness analysis of pembrolizumab plus chemotherapy as first-line therapy for extensive-stage small-cell lung cancer

Chongqing Tan, Qiao Liu, Liubao Peng, 2021, PloS one.

Cost-Effectiveness of Avelumab Maintenance Therapy for Advanced or Metastatic Urothelial Carcinoma in the United States

Chongqing Tan, Qiao Liu, Liubao Peng, 2021, Advances in Therapy.

First-Line Atezolizumab for Metastatic NSCLC with High PD-L1 Expression: A United States-Based Cost-Effectiveness Analysis

Chongqing Tan, Qiao Liu, Liubao Peng, 2021, Advances in Therapy.

PD-L1 Test-Based Strategy With Nivolumab as the Second-Line Treatment in Advanced NSCLC： A Cost-Effectiveness Analysis in China

Chongqing Tan, Qiao Liu, Liubao Peng, 2021, Frontiers in Oncology.

First-Line ICI Monotherapies for Advanced Non-small-cell Lung Cancer Patients With PD-L1 of at Least 50%: A Cost-Effectiveness Analysis

Chongqing Tan, Qiao Liu, Liubao Peng, 2021, Frontiers in Pharmacology.

First-line systemic treatment strategies for unresectable hepatocellular carcinoma: A cost-effectiveness analysis

Chongqing Tan, Qiao Liu, X. Wan, 2022, medRxiv.

Cost‐effectiveness of first‐line versus second‐line use of domestic anti‐PD‐1 antibody sintilimab in Chinese patients with advanced or metastatic squamous non‐small cell lung cancer

Qiao Liu, Zhen Zhou, Rihua Cheng, 2022, Cancer medicine.

Cost-Effectiveness of Trastuzumab Deruxtecan for HER2-Low Advanced Breast Cancer in the United States.

Guochun Chen, Chongqing Tan, Qiao Liu, 2023, Clinical therapeutics.

The Cost-Effectiveness of Sugemalimab Plus Chemotherapy as First-Line Treatment for Metastatic Squamous and Non-squamous NSCLC in China.

Qiao Liu, Rihua Cheng, Zhen Zhou, 2023, Advances in therapy.

Economic evaluation of FLOT and ECF/ECX perioperative chemotherapy in patients with resectable gastric or gastro-oesophageal junction adenocarcinoma

Qiao Liu, Xiaohui Zeng, Chunjiang Wang, 2022, BMJ Open.

Biomarkers-Based Cost-Effectiveness of Toripalimab Plus Chemotherapy for Patients with Treatment-Naive Advanced Non-Small Cell Lung Cancer.

Qiao Liu, Zhen Zhou, Huixian Zhang, 2023, Advances in therapy.

Cost-Effectiveness Analysis of Pembrolizumab Plus Chemotherapy in Squamous Non–Small-Cell Lung Cancer in China

Qiao Liu, Huixian Zhang, Lanfang Li, 2023, Risk management and healthcare policy.

Drug Pricing of Domestic Anti-PD-L1 Antibody Adebrelimab: Cost-Effectiveness Analysis of the First-Line ES-SCLC Treatment in China

Qiao Liu, Zhen Zhou, Dongchu Zhou, 2023, Risk management and healthcare policy.